Citations (10)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Omar Maoujoud, Samir Ahid & Yahia Cherrah. (2016) The cost-utility of treating anemia with continuous erythropoietin receptor activator or Epoetin versus routine blood transfusions among chronic hemodialysis patients. International Journal of Nephrology and Renovascular Disease 9, pages 35-43.
Read now
Read now
Holger Schmid. (2016) Methoxy polyethylene glycol-epoetin beta for the treatment of anemia associated with chronic renal failure. Expert Review of Hematology 9:1, pages 5-20.
Read now
Read now
Articles from other publishers (8)
Nan Chen, Changying Xing, Jianying Niu, Bicheng Liu, Junzhou Fu, Jiuyang Zhao, Zhaohui Ni, Mei Wang, Wenhu Liu, Jinghong Zhao, Ling Zhong, Xiongfei Wu, Wenge Li, Yuqing Chen, Wei Shi, Jianghua Chen, Aiping Yin, Ping Fu, Rong Wang, Gengru Jiang, Fanfan Hou, Guohua Ding, Jing Chen, Gang Xu, Yuichiro Kondo, Yuliang Su & Changlin Mei. (2022) Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure: A randomized, open‐label, parallel‐group, non‐inferiority Phase III trail. Chronic Diseases and Translational Medicine 8:1, pages 59-70.
Crossref
Crossref
Hanan AlKharboush, Fatimah Alshehri, Ibrahim Alatwi, Khaled Al Karni, Abdurahman Alatawi & Ahmed M Hamdan. (2020) The Cost-Effectiveness of Using Epoetin-Beta Versus Darbepoetin-Alfa for the Treatment of Anemia Among Chronic Hemodialysis Patients. Cureus.
Crossref
Crossref
Shubhadeep D. Sinha, Vamsi Krishna Bandi, Bala Reddy Bheemareddy, Pankaj Thakur, Sreenivasa Chary, Kalpana Mehta, Vikranth Reddy Pinnamareddy, Rajendra Pandey, Subhramanyam Sreepada & Santosh Durugkar. (2019) Efficacy, tolerability and safety of darbepoetin alfa injection for the treatment of anemia associated with chronic kidney disease (CKD) undergoing dialysis: a randomized, phase-III trial. BMC Nephrology 20:1.
Crossref
Crossref
Luiz H. ArantesJr.Jr., Jeffrey Crawford, Pere Gascon, Mark Latymer, Vincent Launay-Vacher, Catherine Rolland, Florian Scotte & Jay Wish. (2018) A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemia. Critical Reviews in Oncology/Hematology 129, pages 79-90.
Crossref
Crossref
Jagannath H. Saikumar & Csaba P. Kovesdy. 2018. Management of Anemia. Management of Anemia
81
112
.
Astrid Darsonval, Virginie Besson & Claire Cavalin. (2017) Cost-Minimisation Analysis of Erythropoiesis-Stimulating Agents in the Treatment of Anaemia in Dialysed Patients: A Pilot Study. PharmacoEconomics - Open 1:3, pages 223-229.
Crossref
Crossref
Thomas Frietsch. 2016. Transfusionsassoziierte Pharmakotherapie. Transfusionsassoziierte Pharmakotherapie
35
70
.
Omar Maoujoud, Samir Ahid, Hocein Dkhissi, Zouhair Oualim & Yahia Cherrah. (2015) The Cost-Effectiveness of Continuous Erythropoiesis Receptor Activator Once Monthly versus Epoetin Thrice Weekly for Anaemia Management in Chronic Haemodialysis Patients. Anemia 2015, pages 1-9.
Crossref
Crossref